Article ; Online: Triptan medication use among patients with migraine with contraindications in the US.
2022 Volume 62, Issue 7, Page(s) 883–889
Abstract: Objective: We sought to investigate the prevalence of triptan use among patients with migraine who have contraindications to triptan usage, and to explore specifics of the medication prescribed, dosage, and route of administration.: Background: ... ...
| Abstract | Objective: We sought to investigate the prevalence of triptan use among patients with migraine who have contraindications to triptan usage, and to explore specifics of the medication prescribed, dosage, and route of administration. Background: Triptan medications are a mainstay of acute migraine therapy, but little is known about prevalence and patterns of triptan prescribing among patients with contraindications in the United States. Methods: In this retrospective cohort study, we used data from the IBM Marketscan database to identify patients aged ≥ 18 years with migraine from January 1, 2016, to December 31, 2017, using International Classification of Diseases, Clinical Modification 10 codes. Contraindications to triptan medications were identified by review of package labels as listed on the US Food and Drug Administration website. Triptan medications were identified from the IBM Micromedex Redbook linked to prescription claims along with route of administration and dosage. Results: Of 1,038,472 individuals diagnosed with migraine, 400,112 (38.5%) were prescribed triptan medication, and of those who were prescribed a triptan, 55,707 (13.9%) had at least one contraindication, with the most common contraindication being cardiac arrhythmia (33,696/400,112 individuals, 8.4%) followed by cerebrovascular disease (14,787/400,112, 3.7%) and coronary artery disease (10,236/400,112, 2.6%). Sumatriptan was the most prescribed triptan (261,736/1,038,472, 25.2%), and the subcutaneous and intranasal routes were more commonly prescribed among those with contraindications compared with those without contraindications. Discussion: A substantial proportion of patients with migraine with contraindications were prescribed triptan medications. These findings call for further research on the outcomes of patients with medical contraindications who are prescribed triptan medications, and for greater clarity in prescribing guidelines about the optimal approach for acute therapy among patients with migraine. |
|---|---|
| MeSH term(s) | Contraindications ; Humans ; Migraine Disorders/diagnosis ; Migraine Disorders/drug therapy ; Migraine Disorders/epidemiology ; Retrospective Studies ; Serotonin 5-HT1 Receptor Agonists/therapeutic use ; Sumatriptan/therapeutic use ; Tryptamines/therapeutic use ; United States/epidemiology |
| Chemical Substances | Serotonin 5-HT1 Receptor Agonists ; Tryptamines ; Sumatriptan (8R78F6L9VO) |
| Language | English |
| Publishing date | 2022-06-07 |
| Publishing country | United States |
| Document type | Journal Article |
| ZDB-ID | 410130-3 |
| ISSN | 1526-4610 ; 0017-8748 |
| ISSN (online) | 1526-4610 |
| ISSN | 0017-8748 |
| DOI | 10.1111/head.14327 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.B 539: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.